HER2 Breast Cancer

January 3rd 2025

Patients with hormone receptor–positive and human epidermal growth factor receptor 2 breast cancer are particularly at risk.

December 14th 2024

Emerging research in triple-negative breast cancer highlights the promise of molecular-based approaches to improve treatment outcomes.

December 14th 2024

Combining CDK4/6 and PDL-1 inhibitors enhances treatment responses in patients with hormone receptor positive and triple-negative breast cancer.